CHMP insists that generic drugs be market removed after fake trials

Digging its heels in over the summer, the EMA’s expert committee is still of the opinion that almost 100 generic medicines need to be removed from market – though eight have been granted clemency.


At summer meetings debating the issue of fake testing, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has chosen to stick to its guns – nearly 100 generic drugs will have to be removed from market, reports the Danish Medicines Agency.

The reason for this recommendation, which the committee has maintained since May, is due to fraudulent clinical trials conducted by Indian contract research organization (CRO) Synchron Research Service.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs